Monopar Change To Netincome vs Change In Cash Analysis

MNPR Stock

USD 28.54 1.94 6.36%

Monopar Therapeutics financial indicator trend analysis is infinitely more than just investigating Monopar Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Monopar Therapeutics is a good investment. Please check the relationship between Monopar Therapeutics Change To Netincome and its Change In Cash accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.

Change To Netincome vs Change In Cash

Change To Netincome vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Monopar Therapeutics Change To Netincome account and Change In Cash. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Monopar Therapeutics' Change To Netincome and Change In Cash is 0.4. Overlapping area represents the amount of variation of Change To Netincome that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Monopar Therapeutics, assuming nothing else is changed. The correlation between historical values of Monopar Therapeutics' Change To Netincome and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Netincome of Monopar Therapeutics are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Change To Netincome i.e., Monopar Therapeutics' Change To Netincome and Change In Cash go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Change To Netincome

Change In Cash

Most indicators from Monopar Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.As of 01/18/2025, Selling General Administrative is likely to drop to about 2.2 M. In addition to that, Tax Provision is likely to drop to about (67.7 K)

	2022	2023	2024	2025 (projected)
Total Operating Expenses	10.5M	8.8M	10.2M	7.5M
Research Development	7.6M	5.6M	6.4M	5.3M

Total Operating Expenses Research Development

Monopar Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Total Liab	Total Current Assets	Other Current Liab	Net Debt	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Common Stock Total Equity	Net Invested Capital	Net Working Capital	Common Stock	Capital Stock	Retained Earnings Total Equity	Short Long Term Debt Total	Short Term Debt
Total Assets		0.65	0.99	0.78	-0.69	0.65	0.98	0.65	1.0	0.1	-0.97	-0.76	1.0	0.32	0.83	0.33	0.75	0.66	0.7	0.77	0.47	0.47	0.1	-0.16	-0.16
Total Current Liabilities	0.65		0.54	0.91	-0.89	1.0	0.55	1.0	0.67	0.44	-0.51	-0.77	0.67	0.76	0.86	0.08	0.9	0.86	0.1	0.19	0.83	0.83	0.37	-0.25	-0.25
Total Stockholder Equity	0.99	0.54		0.7	-0.6	0.54	0.99	0.54	0.99	0.04	-0.98	-0.7	0.99	0.22	0.76	0.35	0.67	0.57	0.76	0.82	0.37	0.37	0.04	-0.13	-0.13
Net Tangible Assets	0.78	0.91	0.7		-0.93	0.91	0.75	0.91	0.8	0.5	-0.72	-0.85	0.79	0.8	0.98	0.18	0.99	0.93	0.2	0.29	0.88	0.88	0.43	-0.25	-0.25
Retained Earnings	-0.69	-0.89	-0.6	-0.93		-0.89	-0.65	-0.89	-0.71	-0.7	0.58	0.89	-0.72	-0.83	-0.93	-0.24	-0.97	-0.89	-0.08	-0.17	-0.9	-0.9	-0.5	0.48	0.48
Accounts Payable	0.65	1.0	0.54	0.91	-0.89		0.55	1.0	0.67	0.44	-0.51	-0.77	0.67	0.76	0.86	0.08	0.9	0.86	0.1	0.19	0.83	0.83	0.37	-0.25	-0.25
Cash	0.98	0.55	0.99	0.75	-0.65	0.55		0.55	0.98	0.14	-0.99	-0.75	0.98	0.32	0.81	0.35	0.73	0.65	0.71	0.77	0.46	0.46	0.13	-0.17	-0.17
Total Liab	0.65	1.0	0.54	0.91	-0.89	1.0	0.55		0.67	0.44	-0.51	-0.77	0.67	0.76	0.86	0.08	0.9	0.86	0.1	0.19	0.83	0.83	0.37	-0.25	-0.25
Total Current Assets	1.0	0.67	0.99	0.8	-0.71	0.67	0.98	0.67		0.12	-0.96	-0.78	1.0	0.34	0.85	0.34	0.77	0.68	0.68	0.75	0.49	0.49	0.11	-0.16	-0.16
Other Current Liab	0.1	0.44	0.04	0.5	-0.7	0.44	0.14	0.44	0.12		0.0	-0.51	0.15	0.82	0.47	-0.02	0.6	0.66	-0.3	-0.24	0.79	0.81	0.79	-0.79	-0.79
Net Debt	-0.97	-0.51	-0.98	-0.72	0.58	-0.51	-0.99	-0.51	-0.96	0.0		0.69	-0.96	-0.23	-0.77	-0.35	-0.68	-0.57	-0.72	-0.78	-0.38	-0.38	0.01	-0.01	-0.01
Non Current Assets Total	-0.76	-0.77	-0.7	-0.85	0.89	-0.77	-0.75	-0.77	-0.78	-0.51	0.69		-0.79	-0.64	-0.91	-0.44	-0.9	-0.81	-0.21	-0.32	-0.74	-0.74	-0.38	0.38	0.38
Cash And Short Term Investments	1.0	0.67	0.99	0.79	-0.72	0.67	0.98	0.67	1.0	0.15	-0.96	-0.79		0.35	0.84	0.32	0.77	0.68	0.69	0.76	0.5	0.5	0.13	-0.2	-0.2
Common Stock Shares Outstanding	0.32	0.76	0.22	0.8	-0.83	0.76	0.32	0.76	0.34	0.82	-0.23	-0.64	0.35		0.72	0.01	0.83	0.89	-0.21	-0.13	0.98	0.98	0.76	-0.5	-0.5
Capital Surpluse	0.83	0.86	0.76	0.98	-0.93	0.86	0.81	0.86	0.85	0.47	-0.77	-0.91	0.84	0.72		0.3	0.98	0.89	0.22	0.32	0.82	0.81	0.4	-0.26	-0.26
Other Current Assets	0.33	0.08	0.35	0.18	-0.24	0.08	0.35	0.08	0.34	-0.02	-0.35	-0.44	0.32	0.01	0.3		0.25	0.0	0.03	0.08	0.0	0.01	-0.02	-0.02	-0.02
Other Stockholder Equity	0.75	0.9	0.67	0.99	-0.97	0.9	0.73	0.9	0.77	0.6	-0.68	-0.9	0.77	0.83	0.98	0.25		0.93	0.14	0.24	0.9	0.9	0.49	-0.36	-0.36
Common Stock Total Equity	0.66	0.86	0.57	0.93	-0.89	0.86	0.65	0.86	0.68	0.66	-0.57	-0.81	0.68	0.89	0.89	0.0	0.93		0.17	0.26	0.95	0.95	0.65	-0.46	-0.46
Net Invested Capital	0.7	0.1	0.76	0.2	-0.08	0.1	0.71	0.1	0.68	-0.3	-0.72	-0.21	0.69	-0.21	0.22	0.03	0.14	0.17		0.99	-0.07	-0.06	-0.2	-0.01	-0.01
Net Working Capital	0.77	0.19	0.82	0.29	-0.17	0.19	0.77	0.19	0.75	-0.24	-0.78	-0.32	0.76	-0.13	0.32	0.08	0.24	0.26	0.99		0.02	0.02	-0.15	-0.05	-0.05
Common Stock	0.47	0.83	0.37	0.88	-0.9	0.83	0.46	0.83	0.49	0.79	-0.38	-0.74	0.5	0.98	0.82	0.0	0.9	0.95	-0.07	0.02		1.0	0.7	-0.48	-0.48
Capital Stock	0.47	0.83	0.37	0.88	-0.9	0.83	0.46	0.83	0.49	0.81	-0.38	-0.74	0.5	0.98	0.81	0.01	0.9	0.95	-0.06	0.02	1.0		0.71	-0.52	-0.52
Retained Earnings Total Equity	0.1	0.37	0.04	0.43	-0.5	0.37	0.13	0.37	0.11	0.79	0.01	-0.38	0.13	0.76	0.4	-0.02	0.49	0.65	-0.2	-0.15	0.7	0.71		-0.8	-0.8
Short Long Term Debt Total	-0.16	-0.25	-0.13	-0.25	0.48	-0.25	-0.17	-0.25	-0.16	-0.79	-0.01	0.38	-0.2	-0.5	-0.26	-0.02	-0.36	-0.46	-0.01	-0.05	-0.48	-0.52	-0.8		1.0
Short Term Debt	-0.16	-0.25	-0.13	-0.25	0.48	-0.25	-0.17	-0.25	-0.16	-0.79	-0.01	0.38	-0.2	-0.5	-0.26	-0.02	-0.36	-0.46	-0.01	-0.05	-0.48	-0.52	-0.8	1.0

Click cells to compare fundamentals

Monopar Therapeutics Account Relationship Matchups

Monopar Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	16.9M	20.5M	13.2M	7.3M	8.4M	11.5M
Total Current Liabilities	1.2M	1.6M	3.1M	1.8M	2.0M	1.1M
Total Stockholder Equity	15.7M	18.9M	10.1M	5.6M	6.4M	10.4M
Net Tangible Assets	6.9M	12.6M	15.7M	18.9M	21.8M	10.9M
Retained Earnings	(32.2M)	(41.3M)	(51.8M)	(60.2M)	(54.2M)	(51.5M)
Accounts Payable	1.2M	1.6M	3.1M	1.8M	2.0M	1.1M
Cash	16.7M	20.3M	8.2M	7.3M	8.4M	10.5M
Total Liab	1.2M	1.6M	3.1M	1.8M	2.0M	1.1M
Total Current Assets	16.8M	20.5M	13.2M	7.3M	8.4M	11.2M
Other Current Liab	1.2M	1.6M	(48.6K)	1.8B	2.0B	2.1B
Net Debt	(16.7M)	(20.3M)	(8.2M)	(7.3M)	(6.5M)	(6.9M)
Cash And Short Term Investments	16.7M	20.3M	13.1M	7.3M	8.4M	12.2M
Common Stock Shares Outstanding	11.0M	12.5M	12.7M	14.5M	16.7M	12.7M
Liabilities And Stockholders Equity	16.9M	20.5M	13.2M	7.3M	8.4M	12.6M
Other Current Assets	62.7K	217.7K	46.0K	66.4K	59.8K	99.5K
Other Stockholder Equity	47.9M	60.2M	61.9M	65.8M	75.7M	46.1M
Net Invested Capital	15.7M	18.9M	10.1M	5.6M	6.4M	12.5M
Net Working Capital	15.6M	18.9M	10.0M	5.6M	6.4M	12.3M
Common Stock	11.5K	12.6K	12.9K	14.9K	17.1K	12.7K
Accumulated Other Comprehensive Income	(7.9K)	(3.2K)	8.9K	(14.1K)	(16.3K)	(15.4K)
Capital Stock	11.5K	12.6K	12.9K	14.9K	17.1K	13.2K

Pair Trading with Monopar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Monopar Stock

0.64

DMAC

DiaMedica Therapeutics

Pair Corr

Moving against Monopar Stock

0.79	VINC	Vincerx Pharma	Pair Corr
0.78	DTIL	Precision BioSciences	Pair Corr
0.78	VIGL	Vigil Neuroscience	Pair Corr
0.74	ME	23Andme Holding	Pair Corr
0.72	VALN	Valneva SE ADR	Pair Corr

The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.

The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC